Inside Germany’s Evolving Access Landscape
Germany's GKV-BStabG Reform: What It Really Means for Pharma
Seven provisions. Two that help industry. Five that do not. This whitepaper provides a structured, provision-by-provision assessment of what was proposed, what is likely to pass, and what your P&MA team must do now.
Why download?
Understand which provisions are most likely to pass - and how they combine to reshape German market economics
Stress-test your revenue assumptions against a range of passage and implementation scenarios
Identify whether your portfolio, therapy area, or lifecycle stage faces above-average exposure
Equip your leadership team with a structured, evidence-based briefing before the July deadline
Gain a clear plan your P&MA team can act on
What's inside?
Provision-by-provision analysis - Independent assessment of all seven measures in plain language.
Passage probability - Which provisions will pass as drafted, and which are likely to be narrowed.
Scenario modelling guidance - Frameworks to stress-test revenue assumptions under different outcomes.
Most affected companies & therapy areas - Which portfolios and indications face the greatest exposure.
Leadership discussion framework — Structured questions to align cross-functional teams.
This Resource is Essential For: Global Pricing and Market Access leaders, Launch and Lifecycle Excellence leaders, HEOR and Evidence Strategy leads, who are seeking a structured way to think through the strategic implications of the GKV-BStabG reform.
Download the whitepaper
